8-溴-1,3-二甲基-7-(2-苯基乙基)嘌呤-2,6-二酮 | 228247-60-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 中文名称: 8-溴-1,3-二甲基-7-(2-苯基乙基)嘌呤-2,6-二酮
• 英文名称: 7-(2-phenylethyl)-8-bromo-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione
• 英文别名: 7-phenethyl-8-bromotheophylline；8-bromo-1,3-dimethyl-7-phenethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione；8-bromo-1,3-dimethyl-7-(2-phenylethyl)purine-2,6-dione
• CAS: 228247-60-7
• 化学式: C₁₅H₁₅BrN₄O₂
• 分子量: 363.214
• InChiKey: LKPLLCQMOAHILQ-UHFFFAOYSA-N

物化性质

• 沸点：
  541.9±60.0 °C(Predicted)
• 密度：
  1.57±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  58.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  8-溴-1,3-二甲基-7-(2-苯基乙基)嘌呤-2,6-二酮 在 氢溴酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 8-((3,4-dihydroxyphenethyl)amino)-1,3-dimethyl-7-phenethyl-3,7-dihydro-1H-purine-2,6-dione
  参考文献：
  名称：

  Xanthine–Dopamine Hybrid Molecules as Multitarget Drugs with Potential for the Treatment of Neurodegenerative Diseases

  摘要：

  基于多巴胺-黄嘌呤混合核心的多靶点药物被设计为治疗神经退行性疾病的潜在候选药物。进一步开发的单胺氧化酶 B（MAO-B）抑制剂具有显著的辅助 A2A 腺苷受体（A2AAR）拮抗特性，可表现出额外的磷酸二酯酶-4 和-10（PDE4/10）抑制和/或多巴胺 D2 受体（D2R）激动活性。虽然所有设计的化合物都显示出纳摩尔范围内的 MAO-B 抑制作用，而且大多结合了亚摩尔级 A2AAR 亲和力，但通过各种结构修饰，一些化合物的 PDE 抑制和 D2R 激动活性得到了显著增强。最终的多靶点药物还在体外显示出良好的抗氧化特性。为了评估其潜在的神经保护作用，代表性配体在毒素诱导的神经毒性细胞模型中进行了测试。结果发现，这些药物对神经母细胞瘤细胞的氧化应激具有保护作用，从而证实了这种应用策略的实用性。有必要在阿尔茨海默氏症和帕金森氏症的临床前模型中进一步评估新开发的多靶点配体。

  DOI：

  10.3390/biom13071079
• 作为产物：
  描述：

  8-溴茶碱 在 苄基三乙基氯化铵 、 potassium carbonate 作用下， 以 丙酮 为溶剂， 生成 8-溴-1,3-二甲基-7-(2-苯基乙基)嘌呤-2,6-二酮
  参考文献：
  名称：

  Xanthine–Dopamine Hybrid Molecules as Multitarget Drugs with Potential for the Treatment of Neurodegenerative Diseases

  摘要：

  基于多巴胺-黄嘌呤混合核心的多靶点药物被设计为治疗神经退行性疾病的潜在候选药物。进一步开发的单胺氧化酶 B（MAO-B）抑制剂具有显著的辅助 A2A 腺苷受体（A2AAR）拮抗特性，可表现出额外的磷酸二酯酶-4 和-10（PDE4/10）抑制和/或多巴胺 D2 受体（D2R）激动活性。虽然所有设计的化合物都显示出纳摩尔范围内的 MAO-B 抑制作用，而且大多结合了亚摩尔级 A2AAR 亲和力，但通过各种结构修饰，一些化合物的 PDE 抑制和 D2R 激动活性得到了显著增强。最终的多靶点药物还在体外显示出良好的抗氧化特性。为了评估其潜在的神经保护作用，代表性配体在毒素诱导的神经毒性细胞模型中进行了测试。结果发现，这些药物对神经母细胞瘤细胞的氧化应激具有保护作用，从而证实了这种应用策略的实用性。有必要在阿尔茨海默氏症和帕金森氏症的临床前模型中进一步评估新开发的多靶点配体。

  DOI：

  10.3390/biom13071079

文献信息

• New 8-aminoalkyl derivatives of purine-2,6-dione with arylalkyl, allyl or propynyl substituents in position 7, their 5-HT1A, 5-HT2A, and 5-HT7 receptor affinity and pharmacological evaluation
  作者：Grażyna Chłoń-Rzepa、Paweł Żmudzki、Grzegorz Satała、Beata Duszyńska、Anna Partyka、Dagmara Wróbel、Magdalena Jastrzębska-Więsek、Anna Wesołowska、Andrzej J. Bojarski、Maciej Pawłowski、Paweł Zajdel

  DOI：10.1016/s1734-1140(13)70960-5

  日期：2013.1

  Background: Our previous studies in a group of arylpiperazine derivatives of 1,3-dimethyl-3,7-dihydro-purine-2,6-diones, aimed at chemical diversification of the purine-2,6-dione by introduction of hydrophobic substituent in a 7- or 8- position or elongation of the linker length between arylpiperazine and purine core, allowed a selection of potent 5-HT1A, 5-HT2A and 5-HT7 receptor ligands displaying anxiolytic and antidepressant properties. Continuing our research in this field, in the present studies we designed a new series of 8-aminoalkylamino (15-35) and 8-arylpiperazinylpropoxy (36-42) derivatives of 7-substituted 1,3-dimethyl-3,7-dihydropurine-2,6-dione as potential 5-HT1A, 5-HT2A and 5-HT7 receptor ligands with potential psychotropic activity. Methods: Radioligand binding assays were employed for determining the affinity and the selectivity profile of the synthesized compounds for native 5-HT1A, 5-HT2A, and cloned 5-HT6 and 5-HT7 receptors. The functional activity of the selected compounds at 5-HT1A and 5-HT2A receptors was tested in the commonly used in vivo models. Antidepressant and anxiolytic properties were evaluated in the forced swim (FST) and the four-plate test (FPT) in mice, respectively. Results: Among the evaluated series, selected 7-benzyl-8-((4-(4-(3-chlorophenyl)piperazin-1-yl)butyl)amino)-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione (21), a mixed 5-HT1A/5-HT2A/5-HT7 receptor ligand, produced an antidepressant-like effect in FST, and exerted anxiolytic-like activity in FPT. Another pharmacologically evaluated compound 42 (a mixed 5-HT1A/5-HT7 ligand) slightly, but non-significantly attenuated the immobility time of mice in FST and was devoid of activity in FPT. Conclusions: Study revealed advantage of mixed 5-HT1A/5-HT2A/5-HT7 receptor ligands over 5-HT1A/5-HT7 agents to display antidepressant- and anxiolytic-like activity. Modification of arylalkyl/allyl substituent in position 7 of purine-2,6-dione opens possibility for designing new 5-HT ligands with preserved p electron system and lower molecular weight.
• Drabczynska; Karolak-Wojciechowska; Kiec-Kononowicz, Polish Journal of Chemistry, 1999, vol. 73, # 5, p. 783 - 792
  作者：Drabczynska、Karolak-Wojciechowska、Kiec-Kononowicz

  DOI：——

  日期：——
• Xanthine–Dopamine Hybrid Molecules as Multitarget Drugs with Potential for the Treatment of Neurodegenerative Diseases
  作者：Michał Załuski、Tadeusz Karcz、Anna Drabczyńska、Christin Vielmuth、Agnieszka Olejarz-Maciej、Monika Głuch-Lutwin、Barbara Mordyl、Agata Siwek、Grzegorz Satała、Christa E. Müller、Katarzyna Kieć-Kononowicz

  DOI：10.3390/biom13071079

  日期：——

  Multitarget drugs based on a hybrid dopamine–xanthine core were designed as potential drug candidates for the treatment of neurodegenerative diseases. Monoamine oxidase B (MAO-B) inhibitors with significant ancillary A2A adenosine receptor (A2AAR) antagonistic properties were further developed to exhibit additional phosphodiesterase-4 and -10 (PDE4/10) inhibition and/or dopamine D2 receptor (D2R) agonistic activity. While all of the designed compounds showed MAO-B inhibition in the nanomolar range mostly combined with submicromolar A2AAR affinity, significant enhancement of PDE-inhibitory and D2R-agonistic activity was additionally reached for some compounds through various structural modifications. The final multitarget drugs also showed promising antioxidant properties in vitro. In order to evaluate their potential neuroprotective effect, representative ligands were tested in a cellular model of toxin-induced neurotoxicity. As a result, protective effects against oxidative stress in neuroblastoma cells were observed, confirming the utility of the applied strategy. Further evaluation of the newly developed multitarget ligands in preclinical models of Alzheimer’s and Parkinson’s diseases is warranted.

  基于多巴胺-黄嘌呤混合核心的多靶点药物被设计为治疗神经退行性疾病的潜在候选药物。进一步开发的单胺氧化酶 B（MAO-B）抑制剂具有显著的辅助 A2A 腺苷受体（A2AAR）拮抗特性，可表现出额外的磷酸二酯酶-4 和-10（PDE4/10）抑制和/或多巴胺 D2 受体（D2R）激动活性。虽然所有设计的化合物都显示出纳摩尔范围内的 MAO-B 抑制作用，而且大多结合了亚摩尔级 A2AAR 亲和力，但通过各种结构修饰，一些化合物的 PDE 抑制和 D2R 激动活性得到了显著增强。最终的多靶点药物还在体外显示出良好的抗氧化特性。为了评估其潜在的神经保护作用，代表性配体在毒素诱导的神经毒性细胞模型中进行了测试。结果发现，这些药物对神经母细胞瘤细胞的氧化应激具有保护作用，从而证实了这种应用策略的实用性。有必要在阿尔茨海默氏症和帕金森氏症的临床前模型中进一步评估新开发的多靶点配体。